KR20230146214A - The production method for COVID-19 antibodies and vaccines by using eggs produced by hens - Google Patents
The production method for COVID-19 antibodies and vaccines by using eggs produced by hens Download PDFInfo
- Publication number
- KR20230146214A KR20230146214A KR1020220044902A KR20220044902A KR20230146214A KR 20230146214 A KR20230146214 A KR 20230146214A KR 1020220044902 A KR1020220044902 A KR 1020220044902A KR 20220044902 A KR20220044902 A KR 20220044902A KR 20230146214 A KR20230146214 A KR 20230146214A
- Authority
- KR
- South Korea
- Prior art keywords
- eggs
- chickens
- antibodies
- vaccine
- corona vaccine
- Prior art date
Links
- 235000013601 eggs Nutrition 0.000 title claims abstract description 62
- 229960005486 vaccine Drugs 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 208000025721 COVID-19 Diseases 0.000 title 1
- 241000287828 Gallus gallus Species 0.000 claims abstract description 50
- 235000013330 chicken meat Nutrition 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000003442 weekly effect Effects 0.000 claims abstract description 12
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 8
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 8
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 5
- 241001474374 Blennius Species 0.000 claims abstract description 5
- 240000004160 Capsicum annuum Species 0.000 claims abstract description 5
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims abstract description 5
- 235000007862 Capsicum baccatum Nutrition 0.000 claims abstract description 5
- 241000251511 Holothuroidea Species 0.000 claims abstract description 5
- 235000015278 beef Nutrition 0.000 claims abstract description 5
- 239000001728 capsicum frutescens Substances 0.000 claims abstract description 5
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 4
- 244000046052 Phaseolus vulgaris Species 0.000 abstract 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229940027941 immunoglobulin g Drugs 0.000 description 11
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 210000002969 egg yolk Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 235000013345 egg yolk Nutrition 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001584 effect on egg Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/22—Animal feeding-stuffs from material of animal origin from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/807—Poultry or ruminant feed
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Botany (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
본 발명은 제1실시예로서, 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법에 관한 것이며, 제2실시예로서, 사료 40% 중량에 해삼 10% 중량, 홍삼건조물 10% 중량, 소고기 10%중량, 나머지는 미역다시마, 서리테콩, 고추씨, 버섯을 각각 균일한 중량으로 첨가하여 혼합한 혼합사료으로 먹인 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법을 제공하는데 있다.
이는 별도의 코로나 백신을 투여받지 않아도, 일상적으로 쉽게 접근할 수 있는 계란에 코로나 백신항체를 포함하는 기능성 계란을 생산하여, 평상시에 용이하게 코로나 백신항체를 인체에 스며들게 하는 효과를 제공하는 것이다.
The present invention, as a first embodiment, relates to a method for producing eggs with a corona vaccine antibody using chickens in which the corona vaccine is included in the eggs produced after administration to 14-week-old chickens four times at weekly intervals, As a second example, 40% by weight of feed, 10% by weight of sea cucumber, 10% by weight of dried red ginseng, 10% by weight of beef, and the remainder are mixed feed by adding equal weights of seaweed kelp, seorite beans, red pepper seeds, and mushrooms. The aim is to provide a method of producing eggs with corona vaccine antibodies using chickens in which the corona vaccine is included in the produced eggs after administration to fed 14-week-old chickens four times at weekly intervals.
This is to produce functional eggs containing corona vaccine antibodies in eggs that are easily accessible on a daily basis, even without receiving a separate corona vaccine, providing the effect of easily infiltrating the corona vaccine antibodies into the human body on a daily basis.
Description
본 발명은 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법으로서, 더욱 상세하게는 본 발명은 닭에 주기적으로 코로나 백신을 투여하고, 코로나 백신을 투여받은 닭이 생산한 계란에, 코로나 백신성분이 포함되도록 형성하여, 사람이 계란을 먹음으로 인하여, 별도의 코로나 백신을 투여받을 필요없이 인체 내부에 코로나 백신성분이 튜입되도록 하는 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법에 관한 것이다.The present invention is a method of producing eggs with a corona vaccine antibody using chickens. More specifically, the present invention involves periodically administering a corona vaccine to chickens, and adding corona vaccine ingredients to eggs produced by chickens administered the corona vaccine. It relates to a method of producing eggs with corona vaccine antibodies using chickens, which are formed so that when a person eats the egg, the corona vaccine component is injected into the human body without the need to receive a separate corona vaccine.
지금것 특수란에 대한 발명은 여러가지로 이루워져 왔다. 산란계 사료에 지방산 조성을 달리한 지방급원을 먹임으로써 특수란을 생산하기도 하는 등 사료조성을 달리하여 계란에서의 조성을 달리하는 여러 가지 방법이 있으나 주로 지방과 비타민 혹은 다름 첨가제 등을 통하여 영양적 가치나 기호도를 증진시키고자 하였다. Inventions regarding special eggs have been made in various ways. There are many ways to vary the composition of eggs by varying the composition of the feed, such as producing special eggs by feeding fat sources with different fatty acid compositions to laying hen feed, but nutritional value or preference is mainly increased through fat, vitamins, or other additives. wanted to promote it.
종래에는 대부분 항원특이면역글로불린 G(Antigen-specific immunoglobulin G : IgG)을 여러 분야에서 폭 넓게 이용되고있다. 특히, IgG는 면역이 아직 생성되지 않은 개인이나 동물에게 투여함으로써 수동 면역치료(passive immunization therapy)에 이용되고 있다. Conventionally, antigen-specific immunoglobulin G (IgG) has been widely used in various fields. In particular, IgG is used for passive immunization therapy by administering it to individuals or animals who have not yet developed immunity.
지금까지 IgG는 토끼, 소, 염소 등과 같은 포유류의 혈청이나 초유로부터 분리되어져 왔으며 그 중 토끼를 주로 사용하였다. Until now, IgG has been isolated from serum or colostrum of mammals such as rabbits, cows, goats, etc., and rabbits were mainly used.
조류에서 얻어지는 항체는 포유류의 항체보다 더 많은 이점이 있음에도 불구하고 아직은 관습상 포유류에 의한 항체를 주로 이용하고 있다. Although antibodies obtained from birds have many advantages over mammalian antibodies, mammalian antibodies are still mainly used by convention.
작은 포유류에서 혈액을 채취한다는 것은 불편한 작업이며 생산량도 한정적이어서 혈액 이외의 다른 항체 공급원이 없을까 하는 것이 면역계의 관심사이다. Collecting blood from small mammals is an inconvenient task and production is limited, so the immune system is concerned about whether there are other sources of antibodies other than blood.
조류중 쉽게 접할 수 있고 항체 생성이 고도로 발달된 종으로는 닭을 들 수 있다. 닭의 혈액으로 부터도 IgG를 추출할 수 있으나 또 한가지 중요한 급원으로 계란을 들 수 있다. Among birds, chickens are easily encountered and have highly developed antibody production. IgG can also be extracted from chicken blood, but another important source is eggs.
면역의 기본적인 원리로서 모체에 면역을 가지고 있게 되면 그 액성 면역의 본체인 항체는 젖이나 란의 형태로 어린 새끼에게 전달되어 진다. 즉, 산란계를 면역시키면 그 산란계가 낳은 계란에도 항체가 이행되어 병아리에게 면역성을 부여하게 된다. As a basic principle of immunity, if the mother has immunity, antibodies, which are the main body of humoral immunity, are transmitted to the young in the form of milk or eggs. In other words, when a laying hen is immunized, antibodies are transferred to the eggs laid by the laying hen, giving immunity to the chicks.
이 항체의 양은 산란계의 혈액 중에 있는 IgG 의 양보다는 적지만 산란계의 계속적인 계란 생산을 고려할 때 매우 경제적이라 하겠다. 보통 계란 1개에는 100 ~200mg 의 IgG가 함유되어 있다. Although the amount of this antibody is less than the amount of IgG in the blood of laying hens, it is very economical considering the continuous egg production of laying hens. Usually, one egg contains 100 to 200 mg of IgG.
계란에서 닭의 IgG는 주로 난황에서 발견되며 난백에서는 그 농도가 매우 낮다. 난황 중의 닭의 IgG를 혈청유래의 IgG와 구분하기 위하여 난황면역 글로불린(Yolk immunoglobulins : IgY)라고 부른다. 이 IgY를 난황에서 추출하여 건조시킴으로써 기능성 식품 소재로의 이용이 가능하다. In eggs, chicken IgG is mainly found in egg yolk, and the concentration in egg white is very low. To distinguish chicken IgG in egg yolk from serum-derived IgG, it is called Yolk immunoglobulins (IgY). This IgY can be used as a functional food material by extracting it from egg yolk and drying it.
IgY의 항체는 산란계나 다른 포유류 동물의 혈액 중에 있는 양보다는 적지만 계란은 계속적으로 생산이 되기 때문에 항체 생산면에서 매우 경제적이다. Although the amount of IgY antibodies is less than that in the blood of laying hens or other mammals, eggs are produced continuously, so they are very economical in terms of antibody production.
일반적으로 혈액에서 항체를 얻기 위해서는 동물을 면역시킨 후 혈액 중 항체 농도가 최대에 이르렀을 때 동물을 희생시켜야 한다. 계란 한 개에는 100mg이상의 IgY가함유 되어 있다. Generally, in order to obtain antibodies from the blood, the animal must be immunized and then sacrificed when the antibody concentration in the blood reaches its maximum. One egg contains more than 100 mg of IgY.
산란계 한 마리가 1주일에 생산하는 계란은 5-6개이고 난황 1개의 부피가 약 15㎖정도가 되므로 산란계 1마리가 일주일 동안 생산한 IgY의 양은 산란계 혈청 90-100ml 혹은 전혈 180-200ml에 해당한다. Since one laying hen produces 5-6 eggs per week and the volume of one egg yolk is about 15 ml, the amount of IgY produced by one laying hen in a week is equivalent to 90-100 ml of laying hen serum or 180-200 ml of whole blood. .
토끼 한 마리는 매주 약20ml의 전혈만을 계속적으로 방혈할 수 있으므로 계란에서의 항체 생산량을 1주일간으로 비교할 때 토끼로 부터는 매우 한정된 양만이 생산될 수 있음을 보여준다. 물론 크기가 큰 포유류, 즉 소나 말과 같은 동물에서는 더 많은 양의 혈액을 구할 수 있으나 혈액 채취 과정 등이 매우 시간 소모적이고 고통스러운 일이다. Since one rabbit can continuously bleed only about 20 ml of whole blood each week, when comparing antibody production in eggs per week, it shows that only a very limited amount can be produced from a rabbit. Of course, larger amounts of blood can be obtained from larger mammals, such as cows or horses, but the blood collection process is very time-consuming and painful.
이런 힘든 작업 없이도 면역된 산란계 한 마리당 적어도 1년에 30g의 항체를 얻어낼 수 있는데 이 양은 면역된 토끼에 비해 최소한 120배 정도의 효과가 있는 것이다. Even without this difficult work, at least 30 g of antibodies per year can be obtained from one immunized laying hen, which is at least 120 times more effective than that of an immunized rabbit.
산란계에 항-로타바이러스(anti-human rotavirus:HRV)를 면역시켰을 때 산란율에 전혀 지장을 주지 않았음을 관찰하였고, 1년내내 난황에 높은 면역 역가가 있었다. It was observed that when laying hens were immunized with anti-human rotavirus (HRV), there was no effect on egg laying rate, and there was a high immune titer in egg yolk throughout the year.
난황의 항체는 저장 안정성이 높아 10년간 4℃에서 저장하여도 항체 역가에 유의적인 손실이 없었다고 알려져 있다. 또한 닭과 같은 작은 동물의 백신접종은 비교적 쉽고 반복적으로 수행될 수 있어 편리할 뿐만 아니라 사양과 관리비용이 포유류보다 훨씬 저렴하다. It is known that antibodies in egg yolk have high storage stability and that there was no significant loss in antibody titer even when stored at 4°C for 10 years. In addition, vaccination of small animals such as chickens is not only convenient because it is relatively easy and can be performed repeatedly, but the specification and management costs are much cheaper than those of mammals.
계란에서의 항체량이 전반적으로 높아지게 되면 우리가 원하는 특정한 항체를 얻고자할 때, 특이 항체의 양도 상대적으로 높아지게 된다. 즉 산란계에 특정한 항원을 면역시켰을 때 항체량이 높은 특수란의 경우에는 그 특이 항체의 양이 비율적으로 높아질 수 있다. As the overall amount of antibodies in eggs increases, when we want to obtain the specific antibodies we want, the amount of specific antibodies also becomes relatively high. In other words, when laying hens are immunized with a specific antigen, in the case of special eggs with high antibody content, the amount of that specific antibody may increase proportionally.
최근 몇년동안 코로나 바이러스로 인하여, 전 세계가 일상적인 생활을 못하고 있으며, 종래의 대면문화활동에서 비대면으로 전환되는 정도로 모든 라이프개념이 변화되고 있는 실정이며, 특히 오미크론 바이러스는 전염률이 매우 높으나, 치명률은 독감감기 수준을 유지하고 있으므로, 사람들이 지속적인 백신항체를 갖는 것이 중요한 문제로 대두되고 있다. In recent years, due to the coronavirus, the whole world has been unable to live a normal life, and the entire concept of life is changing to the extent of switching from traditional face-to-face cultural activities to non-face-to-face activities. In particular, the omicron virus has a very high contagion rate. As the fatality rate remains at the level of the flu, it is becoming an important issue for people to have persistent vaccine antibodies.
본 발명은 상기와 같은 문제를 해결하기 위해 안출된 것으로서, 본 발명의 목적은 코로나 백신성분을 갖는 계란을 생산하는 방법을 제공함을 목적으로 한다. The present invention was devised to solve the above problems, and the purpose of the present invention is to provide a method for producing eggs containing coronavirus vaccine components.
본 발명은 상기와 같은 문제점을 해결하기 위한 수단으로서, 본 발명은 The present invention is a means to solve the above problems, and the present invention
제1실시예로서, 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법에 관한 것이며, 제2실시예로서, 사료 40% 중량에 해삼 10% 중량, 홍삼건조물 10% 중량, 소고기 10%중량, 나머지는 미역다시마, 서리테콩, 고추씨, 버섯을 각각 균일한 중량으로 첨가하여 혼합한 혼합사료으로 먹인 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법을 제공하는데 있다.As a first example, it relates to a method of producing eggs with corona vaccine antibodies using chickens in which the corona vaccine is contained in the eggs produced after administration to 14-week-old chickens four times at weekly intervals, and the second example As a result, 14-week-old animals were fed a mixed feed containing 40% of feed, 10% of sea cucumber, 10% of dried red ginseng, 10% of beef, and the remainder was seaweed kelp, soybean, red pepper seed, and mushroom in equal weight. The aim is to provide a method of producing eggs with corona vaccine antibodies using chickens, which are made to contain the corona vaccine in the eggs produced after administering four doses at weekly intervals to the chickens.
이상에서 살펴본 바와 같이, 본 발명은 별도의 코로나 백신을 투여받지 않아도, 일상적으로 쉽게 접근할 수 있는 계란에 코로나 백신항체를 포함하는 기능성 계란을 생산하여, 평상시에 용이하게 코로나 백신항체를 인체에 스며들게 하는 효과를As seen above, the present invention produces functional eggs containing corona vaccine antibodies in eggs that are easily accessible on a daily basis, even without receiving a separate corona vaccine, so that the corona vaccine antibodies can easily permeate into the human body on a daily basis. effect
제공하는 것이다.It is provided.
도 1은 본 발명에 따른 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법을 나타낸 공정도이다. Figure 1 is a process diagram showing a method of producing eggs with corona vaccine antibodies using chickens according to the present invention.
본 발명의 여러 실시예들을 상세히 설명하기 전에, 다음의 상세한 설명에 기재되거나 도면에 도시된 구성요소들의 구성 및 배열들의 상세로 그 응용이 제한되는 것이 아니라는 것을 알 수 있을 것이다. 본 발명은 다른 실시예들로 구현되고 실시될 수 있고 다양한 방법으로 수행될 수 있다. 또, 장치 또는 요소 방향(예를 들어 "전(front)", "후(back)", "위(up)", "아래(down)", "상(top)", "하(bottom)", "좌(left)", "우(right)", "횡(lateral)")등과 같은 용어들에 관하여 본원에 사용된 표현 및 술어는 단지 본 발명의 설명을 단순화하기 위해 사용되고, 관련된 장치 또는 요소가 단순히 특정 방향을 가져야 함을 나타내거나 의미하지 않는다는 것을 알 수 있을 것이다. 또한, "제 1(first)", "제 2(second)"와 같은 용어는 설명을 위해 본원 및 첨부 청구항들에 사용되고 상대적인 중요성 또는 취지를 나타내거나 의미하는 것으로 의도되지 않는다.Before describing the various embodiments of the present invention in detail, it will be appreciated that its application is not limited to the details of the configuration and arrangement of components described in the following detailed description or shown in the drawings. The invention may be embodied and practiced in different embodiments and carried out in various ways. Additionally, device or element orientation (e.g. “front”, “back”, “up”, “down”, “top”, “bottom”). The expressions and predicates used herein with respect to terms such as ", "left", "right", "lateral", etc. are merely used to simplify the description of the invention and related devices. Alternatively, you may notice that it does not simply indicate or imply that an element should have a particular orientation. Additionally, terms such as “first,” “second,” and the like are used herein and in the appended claims for purposes of description and are not intended to indicate or imply relative importance or intent.
본 발명은 상기의 목적을 달성하기 위해 아래의 특징을 갖는다.The present invention has the following features to achieve the above object.
이하 첨부된 도면을 참조로 본 발명의 바람직한 실시예를 상세히 설명하도록 한다. 이에 앞서, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the attached drawings. Prior to this, the terms or words used in this specification and claims should not be construed as limited to their usual or dictionary meanings, and the inventor should appropriately use the concept of terms to explain his or her invention in the best way. It must be interpreted as meaning and concept consistent with the technical idea of the present invention based on the principle of definability.
따라서, 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해하여야 한다.Accordingly, the embodiments described in this specification and the configurations shown in the drawings are only one of the most preferred embodiments of the present invention and do not represent the entire technical idea of the present invention, so at the time of filing this application, various alternatives are available to replace them. It should be understood that equivalents and variations may exist.
본 발명에 따른 실시예를 살펴보면, Looking at an embodiment according to the present invention,
제1실시예로서, As a first embodiment,
본 발명은 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법에 관한 것이다. The present invention relates to a method of producing eggs with corona vaccine antibodies using chickens, which are administered to 14-week-old chickens four times at weekly intervals, and then contain the corona vaccine in the eggs produced.
제2실시예로서는 As a second embodiment,
사료 40% 중량에 해삼 10% 중량, 홍삼건조물 10% 중량, 소고기 10%중량, 나머지는 미역다시마, 서리테콩, 고추씨, 버섯을 각각 균일한 중량으로 첨가하여 혼합한 혼합사료으로 먹인 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 것이다. 14-week-old chickens fed with mixed feed containing 40% of feed, 10% of sea cucumber, 10% of dried red ginseng, 10% of beef, and the remainder by adding even amounts of seaweed kelp, soybeans, red pepper seeds, and mushrooms. After administering four doses at weekly intervals, the eggs produced were made to contain the coronavirus vaccine.
또한, 상기 제2실시예의 상기 혼합사료에 홍삼액기스, 상황버섯 끓인 물을 먹도록 이루어진 것이다. In addition, the mixed feed of the second embodiment is made up of red ginseng extract and water boiled with Sanghwang mushrooms.
이하, 도 1를 참조하여 본 발명의 바람직한 실시예에 따른 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법을 상세히 설명한다. Hereinafter, a method for producing eggs with coronavirus vaccine antibodies using chickens according to a preferred embodiment of the present invention will be described in detail with reference to FIG. 1.
닭은 조류중 쉽게 접할 수 있고 항체 생성이 고도로 발달된 종으로는 닭을 들 수 있다. 닭의 혈액으로 부터도 IgG를 추출할 수 있으나 또 한가지 중요한 급원으로 계란을 들 수 있다. Among birds, chickens are easily encountered and one of the species with highly developed antibody production is chicken. IgG can also be extracted from chicken blood, but another important source is eggs.
면역의 기본적인 원리로서 모체에 면역을 가지고 있게 되면 그 액성 면역의 본체인 항체는 젖이나 란의 형태로 어린 새끼에게 전달되어 진다. 즉, 산란계를 면역시키면 그 산란계가 낳은 계란에도 항체가 이행되어 병아리에게 면역성을 부여하게 되는 원리를 이용하여, 본 발명은 닭에 코로나 백신을 투여하고, 코로나 백신을 투여받은 닭으로부터 생산되는 계란에 관한 것이다.As a basic principle of immunity, if the mother has immunity, antibodies, which are the main body of humoral immunity, are transmitted to the young in the form of milk or eggs. In other words, using the principle that when a laying hen is immunized, antibodies are transferred to the eggs produced by the laying hen, thereby conferring immunity to the chick, the present invention is to administer a corona vaccine to chickens and to eggs produced from chickens that received the corona vaccine. It's about.
본 발명의 제1실시예로서, As a first embodiment of the present invention,
14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법에 관한 것이며, 상기 14주령은 알을 깨고, 14주 기간에 있는 닭을 의미하는 것이다. It relates to a method of producing eggs with corona vaccine antibodies using chickens in which the produced eggs contain the corona vaccine after administering four doses at weekly intervals to 14-week-old chickens, wherein the eggs are broken at 14 weeks of age and the eggs are incubated for 14 weeks. It means chicken in period.
갓 깨어난 닭은 일일령이며, 일주일이 되면, 1주령이라고 하는 것이며, 보통 갓 깨어나서 5개월이면, 20주령부터 알을 낳기 시작하며, 1주령부터 20주령까지 A newly hatched chicken is one day old, and when it is a week old, it is called 1 week old. Usually, when it is 5 months old, it starts laying eggs from 20 weeks of age, and from 1 week to 20 weeks of age.
사료, 주위환경등의 영향에 따라서 계란의 성분이 달라지는 것이다.The composition of eggs varies depending on the influence of feed, surrounding environment, etc.
상기 제1실시예의 사료는 닭의 일반적인 사료를 의미하며, 이러한 일반적인 사료를 먹인 닭이 깨어나서 14주령 될 때에 일주일 간격으로 4회 투여하여, 이 후에 생산되는 계란에는 코로나 백신항체가 가장 많이 포함되어 있으며, 20주령의 닭에 코로나 백신을 투여하여 생산된 계란에는 상대적으로 코로나 백신항체가 감소되어 있는 것을 측정한 결과에 의하여 나타내고 있다. The feed of the first embodiment refers to a general feed for chickens, and is administered 4 times at weekly intervals when chickens fed this general feed wake up and reach 14 weeks of age, and the eggs produced thereafter contain the largest amount of coronavirus vaccine antibodies. , the measurement results show that eggs produced by administering the corona vaccine to 20-week-old chickens have a relative decrease in corona vaccine antibodies.
그러므로, 14주령의 닭에 코로나 백신을 투여하고, 생산된 계란에 최대의 백신항체가 내장되어 있는 것을 알 수 있다. Therefore, it can be seen that the eggs produced by administering the coronavirus vaccine to 14-week-old chickens contain the maximum number of vaccine antibodies.
또한, 본 발명의 제2실시예는 일반 닭사료에 특수첨가물을 혼합한 혼합사료를 먹인 닭에 코로나 백신을 투여하여, 일반 사료를 먹인 닭보다도 코로나 백신항체가 상대적으로 많이 포함되도록 이루어진 것을 특징으로 하는 것이다. In addition, the second embodiment of the present invention is characterized in that the corona vaccine is administered to chickens fed a mixed feed mixed with regular chicken feed and special additives, so that the corona vaccine antibodies are contained in relatively greater quantities than chickens fed regular feed. It is done.
이를 위하여 일반적인 닭사료 40% 중량에 해삼 10% 중량, 홍삼건조물 10% 중량, 소고기 10%중량, 나머지는 미역다시마, 서리테콩, 고추씨, 버섯을 각각 균일한 중량으로 첨가하여 혼합한 혼합사료으로 먹인 14주령의 닭에 일주일 간격으로 4회 투여한 후에, 생산한 계란에 코로나 백신을 포함하도록 이루어진 것이다. For this purpose, 40% of regular chicken feed, 10% of sea cucumber, 10% of dried red ginseng, 10% of beef, and the rest were mixed with equal amounts of seaweed kelp, soybeans, red pepper seeds, and mushrooms. After administering four doses to 14-week-old chickens at weekly intervals, the eggs produced were made to contain the coronavirus vaccine.
상기 일반적인 닭사료는 시중에서 판매하며, 다양한 사료회사에서 판매하는 일반 배합사료를 의미하는 것이며, 시중에서 판매하는 배합사료에 상기 특수 첨가물을 상호 혼합한 혼합사료를 먹인 닭에 코로나 백신을 1주일간격을 4회 투여한 것을 특징으로하며, 이로 인하여 생산되는 계란에는 코로나 백신항체가 상대적으로 많이 포함되어 있는 것이다. The general chicken feed is sold commercially and refers to general compound feed sold by various feed companies. Chickens fed a mixed feed in which the above special additives are mixed with the compound feed sold commercially are administered the coronavirus vaccine at intervals of one week. It is characterized by being administered four times, and the eggs produced as a result contain a relatively large amount of coronavirus vaccine antibodies.
상기 제2실시예는 제1실시에와 동일하게 상기 혼합사료를 먹인 닭이 깨어나서 14주령 될 때에 일주일 간격으로 4회 투여하여, 이 후에 생산되는 계란에는 코로나 백신항체가 가장 많이 포함되어 있으며, 20주령의 닭에 코로나 백신을 투여하여 생산된 계란에는 상대적으로 코로나 백신항체가 감소되어 있는 것을 측정한 결과에 의하여 나타내고 있다. In the second embodiment, the same as in the first embodiment, the chickens fed the mixed feed woke up and were administered four times at weekly intervals when they were 14 weeks old, and the eggs produced after this contained the most corona vaccine antibodies, and 20 Measurement results show that eggs produced by administering the coronavirus vaccine to week-old chickens have relatively reduced levels of coronavirus vaccine antibodies.
그러므로, 14주령의 닭에 코로나 백신을 투여하고, 생산된 계란에 최대의 백신항체가 내장되어 있는 것을 알 수 있다. Therefore, it can be seen that the eggs produced by administering the coronavirus vaccine to 14-week-old chickens contain the maximum number of vaccine antibodies.
또한, 계란에 코로나 백신항체성분을 많이 포함되도록 상기 제2실시예의 상기 혼합사료에 홍삼액기스, 상황버섯 끓인 물을 먹도록 이루어진 것이다. In addition, the mixed feed of the second example is made up of red ginseng extract and boiled water from Sanghwang mushrooms so that the eggs contain a large amount of corona vaccine antibody components.
제1실시예 및 제2실시예에 사용된 코로나 백신은 모더나 백신을 투여한 것이며, 상기 모더나 백신을 포함하여, 다른 화이자 백신이나 다른 의약품회사에서 생산하는 코로나 백신에도 본 발명의 기술적 특징에 포함하는 것은 당연한 것이다.The corona vaccine used in the first and second examples was administered with the Moderna vaccine, and the technical features of the present invention are applied to other Pfizer vaccines and corona vaccines produced by other pharmaceutical companies, including the Moderna vaccine. It is natural to include it.
이상과 같이, 본 발명은 비록 한정된 실시예와 도면에 의해 설명되었으나, 본 발명은 이것에 의해 한정되지 않으며 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 본 발명의 기술 사상과 아래에 기재될 특허청구범위의 균등범위 내에서 다양한 수정 및 변경이 가능함은 물론이다. As described above, although the present invention has been described with limited examples and drawings, the present invention is not limited thereto, and the technical idea of the present invention and the following will be understood by those skilled in the art to which the present invention pertains. Of course, various modifications and changes are possible within the scope of equivalence of the patent claims to be described.
Claims (3)
상기 혼합사료에 홍삼액기스, 상황버섯 끓인 물을 먹도록 이루어진 것을 특징으로 하는 닭을 이용한 코로나 백신항체를 갖는 계란의 생산방법.
According to paragraph 2,
A method of producing eggs with corona vaccine antibodies using chickens, characterized in that the mixed feed is fed with red ginseng extract and water boiled with Sanghwang mushrooms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220044902A KR20230146214A (en) | 2022-04-12 | 2022-04-12 | The production method for COVID-19 antibodies and vaccines by using eggs produced by hens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220044902A KR20230146214A (en) | 2022-04-12 | 2022-04-12 | The production method for COVID-19 antibodies and vaccines by using eggs produced by hens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230146214A true KR20230146214A (en) | 2023-10-19 |
Family
ID=88507864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220044902A KR20230146214A (en) | 2022-04-12 | 2022-04-12 | The production method for COVID-19 antibodies and vaccines by using eggs produced by hens |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230146214A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100286761B1 (en) | 1997-07-22 | 2001-04-16 | 김길환 | Feed for egg-laying hen capable of increasing the content of an immunoprotein and method for eggs containing a large amount of immunoproteins using the same |
| KR100380318B1 (en) | 2000-11-09 | 2003-04-16 | 김대일 | Method for manufacturing the feed for hens using a red ginseng |
-
2022
- 2022-04-12 KR KR1020220044902A patent/KR20230146214A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100286761B1 (en) | 1997-07-22 | 2001-04-16 | 김길환 | Feed for egg-laying hen capable of increasing the content of an immunoprotein and method for eggs containing a large amount of immunoproteins using the same |
| KR100380318B1 (en) | 2000-11-09 | 2003-04-16 | 김대일 | Method for manufacturing the feed for hens using a red ginseng |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| El-Lethey et al. | Stress and feather pecking in laying hens in relation to housing conditions | |
| Warner et al. | The immunological function of the bursa of Fabricius in the chicken | |
| Glick | Extracts from the bursa of Fabricius—a lympho-epithelial gland of the chicken—stimulate the production of antibodies in bursectomized chickens | |
| Gholami et al. | Effects of in ovo administration of betaine and choline on hatchability results, growth and carcass characteristics and immune response of broiler chickens | |
| KR100839807B1 (en) | Transfer factor from birds eggs | |
| Akhlaghi et al. | Oral exposure of broiler breeder hens to extra thyroxine modulates early adaptive immune responses in progeny chicks | |
| Yang et al. | Effects of in ovo injection of Astragalus polysaccharide on the intestinal development and mucosal immunity in broiler chickens | |
| Njagi et al. | Effect of immunosuppression on Newcastle disease virus persistence in ducks with different immune status | |
| Zhao et al. | Effects of dietary vitamin E on immunological stress of layers and their offspring | |
| I Eze et al. | Immune response, anaemia and oxidative stress in Trypanosoma brucei brucei infected rats fed vitamin E supplemented diet | |
| KR20230146214A (en) | The production method for COVID-19 antibodies and vaccines by using eggs produced by hens | |
| Parmentier et al. | Immunological and physiological differences between layer-and broiler chickens after concurrent intratracheal administration of lipopolysaccharide and human serum albumin | |
| Efimenko et al. | Approaches of growing chicken at poultry plants for food industry | |
| Jasim et al. | Effect of In ovo injection of Zinc Methonine on hatching traits, production performance and immunity response of broiler chickens. | |
| KR100286761B1 (en) | Feed for egg-laying hen capable of increasing the content of an immunoprotein and method for eggs containing a large amount of immunoproteins using the same | |
| JP2012158562A (en) | Method for preventing new ulcer disease of carp | |
| Bakhshayesh et al. | The Effects of in ovo injection oil-extracted propolis on growth performance and immune status of broilers | |
| Sandhu et al. | Managing immunocompetence of broiler chicken through vitamin E supplementation at low ambient temperature. | |
| US7579002B2 (en) | Method for improving body weight uniformity and increasing carcass yield in animals | |
| Denton et al. | Effect of injecting and feeding vitamin B12 to hens on content of the vitamin in the egg and blood | |
| Batool | Effect of different lysine regimens on growth, productive and reproductive performance of indigenous Aseel varieties | |
| Ogechi et al. | Effect of experimental single Ancylostoma caninum and mixed infections of Trypanosoma brucei and Trypanosoma congolense on the humoural immune response to anti-rabies vaccination in dogs | |
| Fedorova et al. | Efficiency of Russian white chickens selection as a way to increase vaccine raw material output | |
| Gabarrou et al. | Effect of qualified functional sensory molecules on laying hen’s performances | |
| Saleh | The role of amino acids deficiency in broiler chick’s infection, with Newcastle disease: A review |